(S024) Correlation of Survival to CBCT-Based Tumor Response During Chemoradiation in Patients With Stage III Non–Small-Cell Lung Cancer

Publication
Article
OncologyOncology Vol 28 No 4_Suppl_1
Volume 28
Issue 4_Suppl_1

We evaluated the correlation between patient survival and reduction in gross tumor volume (GTV) using weekly cone-beam computed tomography (CBCT) to assess whether this could be prognostic of survival. We hypothesized that a greater percent decline in primary lung tumor volume during the course of treatment would correlate to improved patient survival.

Salma Jabbour, MD; Rutgers Cancer Institute of New Jersey

Purpose and Objectives: Stage III non–small-cell lung cancer (NSCLC) treated with chemoradiotherapy (CRT) results in a median survival of 15–18 months. We evaluated the correlation between patient survival and reduction in gross tumor volume (GTV) using weekly cone-beam computed tomography (CBCT) to assess whether this could be prognostic of survival. We hypothesized that a greater percent decline in primary lung tumor volume during the course of treatment would correlate to improved patient survival.

Materials and Methods: Patients with stage III NSCLC who received CRT between July 2009 and September 2012 and had daily CBCTs performed as part of their RT course were included in this institutional review board-approved study. Primary GTVs were contoured from CBCT images obtained on Days 1, 8, 15, 22, 29, 36, and 42. Percentage changes in GTV per patient were determined by calculating [(GTV Day 1 – GTV Day 42)/(GTV Day 1)]. MATLAB and Excel 2010 were used to perform t-test analysis of the data, and Kaplan-Meier survival curves were generated based on median GTV reduction with censored patient data. Associations with GTV reduction and time to death were evaluated with a Cox proportional hazards model. 

Results: Thirty-seven patients (median age 67.1 years; standard deviation [SD] = 8.8 years) met the criteria for inclusion in this study from December 2009 to May 2013. Median follow-up was 8.2 months (range: 3–32.9 mo). Median GTV reduction was observed to be 39.2% (range: 0%–79.7%) from Day 1 to Day 42 of radiotherapy. For every 10% decrease in GTV size, the risk of death was lowered by 38.6% (P = .0009). Local recurrence occurred in 29.7% of patients, and distant recurrence occurred in 72.2%. For every 10% reduction in GTV, the risk of local recurrence and distant metastases was lowered by 29.2% (P = .0095) and 26.2% (P = .027), respectively. 

Conclusions: Reductions in primary GTV volume, as determined by weekly CBCT, appear to correlate to patient survival, local recurrence, and distant metastases. Further study with additional patients and longer follow-up is necessary. Such findings may help to determine which patients may also benefit from adaptive planning.

Proceedings of the 96th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(S002) Outcomes and Prognostic Factors of Stereotactic Body Radiotherapy for Soft Tissue Sarcoma Metastases
(S001) Limb-Sparing Surgery and Intraoperative Radiotherapy in the Treatment of Primary, Nonmetastatic Extremity and Limb-Girdle Soft Tissue Sarcoma
(S003) Disparities in Stage at Diagnosis and Survival in Adult Cancer Patients According to Insurance Status
(S004) Radiation Publications Underrepresented in High-Impact General Medical and Oncology Journals 
(S005) Adjuvant Radiotherapy in Stage II Endometrial Carcinoma: Is Brachytherapy Alone Sufficient for Local Control?
(S006) Extended-Field IMRT With Concomitant Boost for Node-Positive Cervical Cancer: Analysis of Regional Control Rate and Recurrence Pattern
(S007) Stereotactic Radiosurgery to the Brain With Concurrent BRAF Inhibitors for Melanoma Metastases
(S008) Use of Mobile Devices for Creation of Survivorship Care Plans
(S009) Two-Year Outcomes Following Triapine Radiochemotherapy for Cervical Cancer 
(S010) Prospective and Real-Time Data Analysis of Image-Guided Radiotherapy Across a Multinational Pediatrics Consortium: Methodology and Considerations 
(S011) Comparison of Toxicities and Outcomes for Conventional and Hypofractionated Radiation Therapy for Early Glottic Carcinoma
(S013) Adjuvant Radiation Therapy and Temozolomide for Anaplastic Gliomas: The Twelve-Year Washington University Experience
(S014) Gamma Knife Stereotactic Radiosurgery in the Treatment of Brainstem Metastases
(S015) Temporal Lobe Radionecrosis After Skull Base Radiotherapy: Dose-Volume Predictors 
(S012) Prognostic Value of Radiographic Extracapsular Extension in Locally Advanced Non-Oropharyngeal Head and Neck Squamous Cell Cancers
Recent Videos
Harmonizing protocols across the health care system may bolster the feasibility of giving bispecifics to those with lymphoma in a community setting.
Although accuracy remains a focus in whole-body MRI testing in patients with Li-Fraumeni syndrome, comfortable testing experiences may ease anxiety.
Subsequent testing among patients in a prospective study may affirm the ability of cfDNA sequencing to detect cancers in those with Li-Fraumeni syndrome.
cfDNA sequencing may allow for more accessible, frequent, and sensitive testing compared with standard surveillance in Li-Fraumeni syndrome.
STX-478 showed efficacy in patients with advanced solid tumors regardless of whether they had kinase domain or helical PI3K mutations.
STX-478 may avoid adverse effects associated with prior PI3K inhibitors that lack selectivity for the mutated protein vs the wild-type protein.
Phase 1 data may show the possibility of rationally designing agents that can preferentially target PI3K mutations in solid tumors.
Funding a clinical trial to further assess liquid biopsy in patients with Li-Fraumeni syndrome may help with detecting cancers early across the board.
Michael J. Hall, MD, MS, FASCO, discusses the need to reduce barriers to care for those with Li-Fraumeni syndrome, including those who live in rural areas.
Related Content